The Effect of Erythromycin in Macrolide-resistant Bordetella pertussis: Inhibitory Effect on Growth, Toxin

Kaichong Jiang1, Yang Luan2, Wei Wang3

  • 1National Regional Children's Medical Center (Northwest), Shaanxi Institute for Pediatric Diseases, Xi'an Children's Hospital, Affiliated Children's Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710003, China.

PubMed
Abstract

Insights

Sub-inhibitory erythromycin may reduce the virulence of macrolide-resistant Bordetella pertussis (MRBp). This finding supports revising macrolide therapy for pertussis and developing new antibiotics against MRBp infections.

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Pharmacology

Background:

  • Macrolide-resistant Bordetella pertussis (MRBp) is prevalent, particularly in China.
  • Macrolides are often the first-line treatment for MRBp infections despite unclear mechanisms.
  • Current macrolide therapy for pertussis requires revision.

Purpose of the Study:

  • To investigate the impact of sub-minimum inhibitory concentrations (sub-MIC) of erythromycin on MRBp virulence.
  • To understand the mechanism of macrolide action on macrolide-resistant Bordetella pertussis.

Main Methods:

  • Evaluated a representative MRBp isolate (BP19147) exposed to varying sub-MIC erythromycin concentrations.
  • Assessed bacterial growth, biofilm formation, and autoaggregation.
  • Utilized RT-qPCR for gene expression analysis and label-free DIA proteomics.

Main Results:

  • Sub-MIC erythromycin inhibited MRBp growth ability and virulence factors in a concentration-dependent manner.
  • Key virulence factors like dermonecrotic toxin and invasive adenylate cyclase were significantly affected (p <0.05).
  • Erythromycin impacted the BvgAS system, biofilm formation, and adaptive systems.

Conclusions:

  • Sub-MIC erythromycin potentially reduces MRBp virulence.
  • Provides a theoretical basis for rational erythromycin use in MRBp infections.
  • Aids in the development of novel antibiotics targeting MRBp.